米国企業
CATALYST PHARMACEUTICALS, INC.

CATALYST PHARMACEUTICALS, INC.CPRX

時価総額

$19.4億

PER

27.2倍

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Product Revenue Net	-	-	-	-	-	-	-	-	-	-	138	214	397
License and other revenue	-	-	-	-	-	-	-	-	-	-	3	0	2
Total revenues	-	-	-	-	-	-	-	500,000	102	119	141	214	398
Cost of sales	-	-	-	-	-	-	-	-	15	17	22	34	52
Research and development	26	28	36	10	12	11	11	20	19	16	17	20	93
Selling, general and administrative	-	-	-	-	-	-	-	-	37	44	50	58	134
Total operating costs and expenses	-	-	-	-	-	-	-	-	-	-	-	112	311
Amortization of intangible assets	-	-	-	-	-	-	-	-	-	-	-	-	33
Total operating costs and expenses	-	-	-	-	-	-	-	-	-	-	-	112	311
Operating income	-6,082,139	-5,221,140	-10,311,658	-14,591,428	-20,398,352	-19,280,201	-18,679,636	-35,295,165	32	41	52	102	87
Other income, net	-	-	-	76,233	100,389	321,612	454,163	1	2	586,897	0	3	8
Operating income	-6,082,139	-5,221,140	-10,311,658	-14,591,428	-20,398,352	-19,280,201	-18,679,636	-35,295,165	32	41	52	102	87
Net income before income taxes	-6,391,062	-4,076,386	-12,154,596	-15,509,061	-20,232,958	-18,072,452	-18,412,377	-34,003,514	33	42	53	105	95
Other income, net	-	-	-	76,233	100,389	321,612	454,163	1	2	586,897	0	3	8
Income tax provision	-	-	-	-	-	-	-	-	2	-33,092,926	13	22	23
Net income before income taxes	-6,391,062	-4,076,386	-12,154,596	-15,509,061	-20,232,958	-18,072,452	-18,412,377	-34,003,514	33	42	53	105	95
Net income	-6,391,062	-4,076,386	-12,154,596	-15,509,061	-20,232,958	-18,072,452	-18,412,377	-34,003,514	32	75	39	83	71
Income tax provision	-	-	-	-	-	-	-	-	2	-33,092,926	13	22	23
Basic	-	-	-	-	-	-	-	-	0.31	0.72	0.38	0.8	0.67
Diluted	-	-	-	-	-	-	-	-	0.3	0.71	0.37	0.75	0.63
Basic	-	-	-	-	-	-	-	-	0.31	0.72	0.38	0.8	0.67
Diluted	-	-	-	-	-	-	-	-	0.3	0.71	0.37	0.75	0.63
Net income	-6,391,062	-4,076,386	-12,154,596	-15,509,061	-20,232,958	-18,072,452	-18,412,377	-34,003,514	32	75	39	83	71
Basic	-	-	-	-	-	-	-	-	0.31	0.72	0.38	0.8	0.67
Diluted	-	-	-	-	-	-	-	-	0.3	0.71	0.37	0.75	0.63
Basic	-	-	-	-	-	-	-	-	0.31	0.72	0.38	0.8	0.67
Diluted	-	-	-	-	-	-	-	-	0.3	0.71	0.37	0.75	0.63
Net income	-6,391,062	-4,076,386	-12,154,596	-15,509,061	-20,232,958	-18,072,452	-18,412,377	-34,003,514	32	75	39	83	71
Unrealized gain (loss) on available-for-sale securities, net of tax of $4, ($54) and $46, respectively	-	-	-	-	-	-	-	-20,248	29,753	21,827	-0	0	-0
Unrealized gain (loss) on available-for-sale securities, net of tax of $4, ($54) and $46, respectively	-	-	-	-	-	-	-	-20,248	29,753	21,827	-0	0	-0
Net income	-6,391,062	-4,076,386	-12,154,596	-15,509,061	-20,232,958	-18,072,452	-18,412,377	-34,003,514	32	75	39	83	71
Unrealized gain (loss) on available-for-sale securities, net of tax of $4, ($54) and $46, respectively	-	-	-	-	-	-	-	-20,248	29,753	21,827	-0	0	-0
Unrealized gain (loss) on available-for-sale securities, net of tax of $4, ($54) and $46, respectively	-	-	-	-	-	-	-	-20,248	29,753	21,827	-0	0	-0
Comprehensive income	-	-	-	-	-	-	-	-34,023,762	32	75	39	83	71
Comprehensive income	-	-	-	-	-	-	-	-34,023,762	32	75	39	83	71